Targeted EGFRt/BCMA-41BBz
Showing 1 - 25 of 5,464
Multiple Myeloma Trial in New York (EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.)
Active, not recruiting
- Multiple Myeloma
- EGFRt/BCMA-41BBz CAR T cell
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 7, 2022
Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)
Recruiting
- Multiple Myeloma
- Human BCMA Targeted T Cells Injection
-
Shanghai, Shanghai, China
- +1 more
Dec 7, 2022
Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)
Recruiting
- Multiple Myeloma
- Plasma Cell Leukemia
- Human BCMA targeted CAR-NK cells injection
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Sep 13, 2023
Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)
Recruiting
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
- BCMA Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022
Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- LUCAR-B68 cells product
-
Xi'an, Shaanxi, ChinaSecond Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))
Active, not recruiting
- Multiple Myeloma
- Elranatamab (PF-06863135)
-
Beverly Hills, California
- +75 more
Oct 4, 2022
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,
Not yet recruiting
- Prostate Carcinoma
- +3 more
- Bendamustine
- +12 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 17, 2023
Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))
Recruiting
- Immunotherapy
- Multiple Myeloma
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Dec 14, 2022
Multiple Myeloma Trial in Beijing, Guangzhou, Shanghai (TQB2934 injection)
Not yet recruiting
- Multiple Myeloma
- TQB2934 injection
-
Beijing, Beijing, China
- +2 more
Dec 8, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022
Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)
Recruiting
- Multiple Myeloma
- anti-BCMA/GPRC5D CAR-T CELL
-
Xuzhou, Jiangsu, ChinaKailin Xu
Aug 19, 2022
Relapsed/Refractory Multiple Myeloma Trial in Beijing, Hangzhou, Shanghai (LCAR-BCDR cells product)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- LCAR-BCDR cells product
-
Beijing, Beijing, China
- +3 more
Dec 15, 2022
Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)
Not yet recruiting
- Multiple Myeloma
- Allogeneic Stem Cell Transplantation
- CARTemis-1
-
Santander, Cantabria, Spain
- +4 more
Aug 1, 2023
Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)
Enrolling by invitation
- Multiple Myeloma
- BCMA CAR T cells
- BCMA/CD19 CAR T cells
-
London, County (optional), United KingdomUniversity College London Hospital
Sep 15, 2022
Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)
Recruiting
- Multiple Myeloma
- New Diagnosis Tumor
- BCMA CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Bone Marrow Aspiration
- +10 more
-
Los Angeles, CaliforniaMelanie Ayala Ceja
Jul 10, 2023
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
- VRD-based regimen
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023
Relapsed/ Refractory Multiple Myeloma Trial (GC012F)
Not yet recruiting
- Relapsed/ Refractory Multiple Myeloma
- GC012F
- (no location specified)
Apr 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Belantamab Mafodotin, Biospecimen
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Belantamab Mafodotin
- +6 more
-
Jacksonville, FloridaMayo Clinic in Florida
Apr 27, 2023
Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)
Recruiting
- Multiple Myeloma
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Biospecimen Collection
- +9 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 1, 2023
Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR
Not yet recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
-
Dresden, GermanyTechnische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023